Annual Report
January 1, 2022 – June 30, 2023
# Table of Contents

- Who We Are .................................................. 1
- Our Strategic Framework ................................. 2
- Our Commitment to Equity, Diversity and Inclusion .... 3
- Timeline of Key Achievements ......................... 4
- Research Impact ............................................. 5
- Knowledge Mobilization and Public Engagement ... 7
- Funding and Partnerships ................................. 8
- Training ..................................................... 9
Who We Are

Our goal is to empower our diverse community of clinicians, engineers, public health experts and scientists to advance innovative infectious disease research and create rapid research response capacity to control emerging pathogens before they become established as a global pandemic.

Launched in January 2022, the Emerging and Pandemic Infections Consortium (EPIC) was born out of a desire to better integrate research and expertise across the University of Toronto and the city’s major hospital research institutes to respond quickly and effectively to infectious disease threats. The COVID-19 pandemic demonstrated what could be achieved when interdisciplinary teams work together towards a common goal.

Building on that momentum, EPIC set out to harness the partnerships, expertise and infrastructure established amongst its partner institutions to combat COVID-19 and use those as a foundation to create a stronger, more dynamic ecosystem of collaboration.

In our first year, we aimed to reinforce the research collaborations forged during the COVID-19 pandemic and amplify the impact of the infectious disease research community through our project and training funding supports. Looking ahead, we will continue to build research response capacity and accelerate research in emerging infectious diseases, ensuring Canada’s health security and supporting other communities in need around the world.

EPIC at a glance

148 Faculty members
85 Trainee members
6 Partner institutions
8 University divisions
13 Industry and government agency partners
Our Strategic Framework

Our aspirational goals

1. Respond rapidly, effectively and equitably to emerging infectious threats through our highly connected and nimble research ecosystem.

2. Advance excellence and diversity in the next generation of research leaders through immersive multidisciplinary learning experiences.

3. Accelerate discovery and translation of scientific innovations that reduce the burden of infectious diseases across affected communities.

To achieve these goals, we will rely on the following five cross-cutting enablers:

- **Multidisciplinary and transformative research** designed to have maximum impact
- **An active and vibrant training environment** that prioritizes collaboration and diversity
- **Partnerships with industry, policy-makers and public health** driven by shared values and goals
- **Cutting-edge infrastructure** providing essential infectious disease research capacity
- **Trusted knowledge leadership** to engage stakeholders across sectors and within the public
Our Commitment to Equity, Diversity and Inclusion

A diverse and inclusive research ecosystem is fundamental to innovation, from the questions we ask to the methods we use to the ideas and solutions that we generate. In our first year, we sought to develop processes that embed equity, diversity and inclusion (EDI) as core values to guide our scientific programming, events, communications, leadership and approach to training and mentorship.

From funding program development to application review to event planning, we are employing strategies to try to address disparities in research and to foster an environment where people with diverse perspectives are valued and can thrive. These strategies include:

**Understanding our community**
By collecting anonymized, self-reported demographic data from applicants to our funding programs, we are capturing a baseline measurement of who is applying for EPIC funding. These data will inform planning for future competitions, including ensuring communications about our programs are reaching diverse research groups.

**Addressing unconscious bias**
All EPIC leadership and review panel members are required to have completed unconscious bias training within the last year from a reputable organization.

**Reviewing for inclusive excellence**
Through the incorporation of standardized evaluation rubrics and feedback tools, we are setting clear expectations for applicants and reviewers in each of our funding competitions. In cases where the demographics of the awardees do not match that of the applicant pool, a "bias-interrupter" will facilitate additional assessments by the review panel or steering committee to reflect on inclusive excellence.

**Prioritized programs**
To attract and retain diverse talent in the infectious disease research ecosystem, we created targeted supports like our Inspire Summer Studentships for Black and Indigenous undergraduate students. We have also prioritized support for early career investigators within each of our funding competitions.

**Transparency**
To enhance accountability, we will publicly share funding processes as well as other relevant information, such as the demographics of our review panels. We will ensure that evaluation rubrics are available to all applicants in our competitions so that expectations for fundable proposals are clear. These processes and information will be published on our website and updated on a regular basis.
# Timeline of Key Achievements

## July
Launched an mpox rapid research response with over $1.1M in committed funding ($250,000 from EPIC and $875,000 in matched funding from EPIC partners)

## November
Received a $35 million grant from Canada Foundation for Innovation for the renewal of the Toronto High Containment Facility (THCF)

Co-hosted a research symposium on antimicrobial resistance with bioMérieux that drew over 250 attendees from across Canada

## February
Launched $1.9 million in research and training supports to advance innovative, interdisciplinary research on infectious diseases

Received a $120,000 gift from GlaxoSmithKline to establish the GSK EPIC Convergence Postdoctoral Fellowship in Antimicrobial Resistance

## March
Launched the Canadian Hub for Health Intelligence and Innovation in Infectious Diseases (HI3) with $2 million in funding from the Canada Biomedical Research Fund

## May
Launched a three-part public speaker series on climate change and infectious diseases in partnership with Climate Positive Energy and the Institute for Pandemics that had over 258 attendees

## June
Cohosted the annual U of T Infectious Diseases and Microbiology Research Day with the Division of Infectious Diseases and MicrobeTO that drew over 275 attendees
Research Impact

The Toronto High Containment Facility (THCF) supports the research of our faculty members in infectious diseases, immunology, genomics and engineering.

The THCF is the largest containment level 3 lab in the province. A cornerstone of EPIC’s research community, it is equipped to allow researchers to study high-risk pathogens, such as SARS-CoV-2, HIV and the bacteria that causes tuberculosis, in a safe and secure way.

During the COVID-19 pandemic, the THCF played a critical role in accelerating key research breakthroughs that guided the pandemic response in Ontario and Canada – including becoming the first lab in Canada, and among the first in the world, to isolate the novel coronavirus in March 2020, an effort led by Sunnybrook researchers Samira Mubareka and Rob Kozak.

The THCF has continued to play a key role in supporting EPIC members’ research over the last 18 months. Notably, it contributed to a study co-led by Mubareka published in Nature Microbiology that describes a highly divergent variant of SARS-CoV-2 in white-tailed deer and the first evidence of deer-to-human transmission. The facility also enabled preclinical evaluation of a new SARS-CoV-2 mRNA vaccine candidate from Providence Therapeutics. The study, which was led by Mario Ostrowski (Unity Health) and published in Science Advances, was instrumental in Providence Therapeutics receiving Health Canada approval to conduct a phase 2 clinical trial to assess their vaccine candidate in humans.

The Toronto High Containment Facility at a glance

- 17 hospital-based groups
- 15 U of T-based groups
- 4 industry-led projects
- 3 projects engaging government agencies
- 37 publications in the last 18 months

In 2021, U of T ranked first in Canada and fifth globally in the number of publications related to COVID-19.

Leading the way in high containment research
Mobilizing against mpox

The global mpox outbreak in 2022 was unprecedented in the amount of local transmission seen in countries where the disease is not endemic.

A week after the first mpox case was detected in Toronto in May 2022, EPIC and its hospital partners, including Sunnybrook Research Institute, Unity Health Toronto and the University Health Network, came together to mount a rapid research response to the global mpox outbreak. The response was led by:

Darrell Tan and Sharmistica Mishra (Unity Health) along with co-investigators Adrienne Chan and Rob Kozak (Sunnybrook), Allison McGeer (Sinai Health), Mario Ostrowski (Unity Health) and Sharon Walmsley (UHN).

Over $1.1 million in funding was committed to support projects including:

- An observational cohort study to better understand disease symptoms
- Modelling studies to look at disease transmission and the impact of varying vaccine distribution
- Transmission studies to understand surface, aerosol, pre-symptomatic and asymptomatic transmission

A central component of the research response was meaningful engagement with the gay, bisexual and men who have sex with men community who were most impacted by the outbreak as well as with community partners.

The work is already having an impact:

- Over $4.8 million in leveraged funding, including a $3.5 million team grant to launch the Canada-Africa mpox Partnership with researchers in Nigeria
- A soon-to-be launched online image atlas featuring images of mpox lesions on different skin tones to reduce stigma and facilitate faster diagnoses
- 11 peer-reviewed articles

Consultations with public health leaders and policymakers to inform vaccine prioritization and outbreak response strategies
Knowledge Mobilization and Public Engagement

8 research and public engagement events
31 stories published on our website highlighting our members and activities
11 stories reshared on Temerty Faculty of Medicine and U of T News websites
21,000+ page views on our stories

---

8 media stories in print, radio, TV and the web
1,008 followers on Twitter
228 followers on LinkedIn
349 subscribers to the newsletter

---

AN EPIC SUCCESS STORY

Bringing people together to address antimicrobial resistance

In November 2022, EPIC partnered with diagnostics industry leader bioMérieux to jointly host a research symposium on Canadian perspectives on antimicrobial resistance: where we are now and looking ahead. The event featured 13 speakers from across Canada, including EPIC members Rob Kozak (Sunnybrook), Karen Maxwell (U of T), Susan Poutanen (Sinai Health/UHN) and Nikki Weckman (U of T), and drew over 250 attendees.

From the clinical perspectives of frontline pharmacists and medical microbiologists to the research advances shared by fundamental researchers, the talks highlighted the need for collaborative, interdisciplinary approaches to tackling this urgent global health challenge. Notably, several speakers underscored the importance of AMR through a One Health lens.

The day ended with an urgent call-to-action for creative solutions to raise the profile of AMR in the public consciousness and among policymakers to boost support for research and measures to tackle AMR and to implement policies that limit its impact.
Funding and Partnerships

$3.0 million
distributed in funding through three project-based and six trainee programs and the mpox rapid research response

$41.8 million
in leveraged funding, including $35 million to revitalize the Toronto High Containment Facility and over $4.8 million to build on projects from the mpox rapid research response

13 industry and government agency partnerships that...

- Advance innovative and collaborative research
- Inform policies and drug and vaccine development
- Support trainee development
- Contribute to EPIC’s long-term sustainability

AN EPIC SUCCESS STORY

Federal funding to enhance pandemic preparedness

Thanks to the leadership of EPIC and our faculty members, U of T received two significant federal investments that will help accelerate critical infectious disease research and allow Canada to respond more quickly, effectively and equitably to future pandemics.

In November 2022, CFI announced a $35 million investment to revitalize the Toronto High Containment Facility (THCF). This research infrastructure funding will support the modernization and expansion of the THCF so that there is increased research capacity to work with emerging and re-emerging pathogens and to maintain existing projects during future pandemics.

In March 2023, U of T became the home for the Canadian Hub for Health Intelligence and Innovation in Infectious Diseases (HI3), an idea borne out of EPIC. The hub brings together over 80 partners in a collaborative, multi-disciplinary and multi-sector coalition that will support a robust domestic pipeline of life-saving vaccines and therapeutics targeting existing and emerging infectious threats.
Training

One of our main goals is to develop an inclusive and multidisciplinary training environment that empowers excellence in the next generation of research leaders. Over the past 18 months, we launched six funding opportunities that specifically support trainees:

- **Inspire Summer Studentships** for third-year Black and Indigenous undergraduate students to undertake infectious disease research
- **Doctoral Awards** to support doctoral students engaged in infectious disease research
- **Future Leaders Prizes** to celebrate PhD graduates who have completed an excellent infectious disease-focused thesis and demonstrated leadership
- **Convergence Postdoctoral Fellowships** to support postdoctoral fellows who are bringing together two distinct research disciplines to address an infectious disease-related question
- **Career Transition Awards** to provide funding to postdoctoral fellows and research associates who are ready to lead an independent, small-scale project
- **Researcher Mobility Awards** to support doctoral students and postdoctoral fellows in undertaking research training or completing collaborative fieldwork outside of Toronto

We have also partnered with MicrobeTO, a U of T-based networking hub for infectious disease-focused trainees, to cohost a social event for trainees and a monthly student seminar series. These trainee-only events provide a safe environment for students to network, discuss their research and build new connections for collaboration. Since January 2022, these events have engaged roughly 93 trainees.

---

**AN EPIC SUCCESS STORY**

**Afia Amoako**

Doctoral Award recipient Afia Amoako is applying a person-centred lens to examine the unequal landscape of the COVID-19 pandemic in Toronto.

Working with David Fisman at the Dalla Lana School of Public Health, her doctoral research aims to combine spatial and mathematical modelling methods with contact tracing, laboratory testing and census data to provide a deeper, more nuanced understanding of how people living in this city experienced COVID-19.

Her project focuses on the first two years of the pandemic when access to PCR testing was more widely available. To capture the missing details about the people affected by COVID-19, Amoako is using data from the 2021 census and the Ontario Marginalization Index, a tool that combines a wide range of demographic indicators to quantify different dimensions of marginalization including poverty and housing.

A moako hopes that her research will lay a foundation for how research on infectious diseases can and should adopt a person-centred approach.

“*We cannot do research on infectious diseases without talking about the diversity of people who are being impacted. There has to be a discussion about people’s diverse experiences – that is what I really want to achieve through my work.*"